Wedbush Reiterates Neutral on Fusion Pharmaceuticals, Maintains $24 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten reiterates a Neutral rating on Fusion Pharmaceuticals (NASDAQ:FUSN) and maintains a $24 price target.

March 21, 2024 | 1:36 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Wedbush analyst David Nierengarten reiterates a Neutral rating on Fusion Pharmaceuticals and maintains a $24 price target.
The reiteration of a Neutral rating and maintenance of a $24 price target by Wedbush suggests a stable outlook for Fusion Pharmaceuticals. This indicates no significant short-term price movement is expected, hence the neutral score. The high relevance is due to the direct mention of FUSN, and the importance is significant as analyst ratings can influence investor perception. The confidence level is high due to the clear stance of the analyst.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100